Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PreFED Diet with Ipilimumab/Nivolumab in ICB-refractory Melanoma
NCT06250335Phase 2Active, not recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Mar 2024
- Primary completion
- Jan 2027
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial in melanoma, sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Overall Response Rate up to 2 years. Started Mar 2024; status: active, not recruiting.
02
Conditions
melanoma
Beyond the preview
Go deeper on NCT06250335.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06250335.